Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Carcinoma, Squamous Cell of Head and Neck Clinical Trial

Official title:

Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02938273
• Other study ID #: N16BIR
• Status: Completed
• Phase: Phase 1
• Start date: February 1, 2017
• Est. completion date: September 30, 2019

Study information

• Verified date: December 2019
• Source: The Netherlands Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy with intravenous administration of cetuximab and avelumab followed by avelumab maintenance therapy in patients with locally advanced head and neck cancer, unfit for cisplatin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 30, 2019
• Est. primary completion date: June 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be willing and able to provide written informed consent for the trial.

• Be =18 years of age on day of signing informed consent.

• WHO Performance Status 0,1 or 2

• Have histologically confirmed Locally Advanced (i.e. stage III or IV) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx.

• Unfit for concurrent chemoradiation with cisplatin, e.g. GFR < 60 ml/min, cardiovascular co-morbidity, hearing loss or polyneuropathy or written refusal for treatment with chemotherapy

• Be willing to provide tissue for tumor microenvironment analysis from archival tumor material (i.e. formalin fixed, paraffin embedded (FFPE) tumor tissue block not older than 42 days before start of treatment) or newly obtained core or excisional biopsy, and willingness to provide a core or excisional biopsy at day 14 (±2 days) after start of treatment.

• Have at least one measurable lesion as defined by RECIST 1.1.

• Be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

• Demonstrate adequate organ function, i.e. adequate bone marrow function, including:

1. Absolute Neutrophil Count (ANC) =1.5 x 109/L;

2. Platelets =100 x 109/L;

3. Hemoglobin =6 mmol/L. Adequate renal function, i.e. estimated creatinine clearance =30 mL/min as calculated using the Cockcroft-Gault (CG) equation (or local institutional standard method).

Adequate liver function, including:

1. Total serum bilirubin =1.5 x ULN;

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN or AST and ALT levels = 5 x ULN (for subjects with documented metastatic disease to the liver).

• Have a negative serum pregnancy test at screening (for females of childbearing potential).

• Both male and female subjects should agree to use highly effective contraception if the risk of conception exists. (Note: The effects of the trial drug on the developing human fetus are unknown; thus, women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year.) Highly effective contraception is required throughout the study and for at least 120 days after Avelumab treatment.

Exclusion Criteria:

• Prior treatment with: Systemic therapy, radiotherapy or surgery directed at locally advanced SCCHN. Immunotherapy with IL-2, IFN-a, or anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.

• A diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

• Current or prior use of immunosuppressive medication within 7 days prior to registration, except the following:

• Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra-articular injection);

• Systemic corticosteroids at physiologic doses =10 mg/day of prednisone or equivalent;

• Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).

• Known severe hypersensitivity reactions to monoclonal antibodies (Grade =3), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more features of partially controlled asthma Global Initiative for Asthma 2011.

• Known prior or suspected hypersensitivity to study drugs or any component in their formulations.

• Diagnosis of any other malignancy within 5 years prior to start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g. surgery, radiation, or castration).

• Significant acute or chronic infections including, among others:

• Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

• Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive)

• Prior organ transplantation, including allogeneic stem cell transplantation

• Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent, except the following:

1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment

2. Subjects requiring hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement and at doses = 10 mg or 10 mg equivalent prednisone per day

3. Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)

• Persisting toxicity related to prior therapy of Grade >1; however, alopecia and sensory neuropathy Grade = 2 is acceptable

• Pregnancy or lactation

• Known alcohol or drug abuse

• All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment

• Any psychiatric condition that would prohibit the understanding or rendering of informed consent

• Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines).

• Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, deep vein thrombosis or symptomatic pulmonary embolism.

• Subjects with brain metastases

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Carcinoma, Squamous Cell of Head and Neck
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• avelumab
Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months

Radiation:
• radiotherapy
5 times a week, 7 weeks, total dose 70 Gy

Drug:
• cetuximab
loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7

Locations

Country	Name	City	State
Netherlands	Antoni van Leeuwenhoek	Amsterdam

Sponsors (2)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	differences in tumor microenvironment	investigate therapy induced changes in tumor microenvironment in tissue biopsies through immunochemistry	prior to treatment and at day 14
Primary	occurence of grade 3-5 toxicity in new combination	according to CTC 4.03	6 months after start of treatment
Secondary	Overall Response Rate		at week 10 and week 26 of treatment